Details of the Drug
General Information of Drug (ID: DM1WL9O)
| Drug Name |
Glycodiazine
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
GLYMIDINE; Glidiazine; Glycodiazin; Glymidinum; Glycodiazin [German]; Gondafon (TN); N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide; N-(5-(2-Methoxyethoxy)-2-pyrimidinyl)benzenesulfonamide; N-(5-(2-Methoxyethoxy)-2-pyrimidinyl)benzenesulphonamide; N-(5-{[2-(methyloxy)ethyl]oxy}pyrimidin-2-yl)benzenesulfonamide; 2-Benzolsulfonamido-5-.beta.-methoxy-aethoxy-pyrimidine; 2-Benzolsulfonamido-5-beta-methoxy-aethoxy-pyrimidine; 2-Benzolsulfonamido-5-beta-methoxy-aethoxy-pyrimidine [German]; 5-beta-(Methoxyethoxy)-2-(phenylsulfonylamido)pyrimidine
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Therapeutic Class |
Hypoglycemic Agents
|
||||||||||||||||||||||
| Affected Organisms |
Humans and other mammals
|
||||||||||||||||||||||
| ATC Code | |||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 309.34 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 0.9 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 7 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 7 | ||||||||||||||||||||||
| ADMET Property |
|
||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||


